慢性淋巴细胞白血病患者的一线治疗：一项系统评价和网状Meta分析。
Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis.
作者信息
Xu Yingxin, Fahrbach Kyle, Dorman Emily, Baculea Simona, Côté Sarah, Sanden Suzy van, Diels Joris
机构信息
Evidera, Waltham, MA, 02451 USA.
Evidera, Bethesda, MD, 20814 USA.
出版信息
J Comp Eff Res. 2018 May;7(5):421-441. doi: 10.2217/cer-2017-0086. Epub 2017 Dec 6.
AIM
A systematic literature review and network meta-analysis were conducted to determine the relative efficacy and safety of interventions for treatment-naive chronic lymphocytic leukemia patients, as comparative evidence is scarce.
MATERIALS & METHODS: Relative treatment effects of progression-free survival, overall survival and safety outcomes were estimated via network meta-analysis based on data identified via systematic literature review.
RESULTS
Ibrutinib was superior in all pairwise comparisons for progression-free survival (probability to be better [P] range: overall population: 69-100%; fludarabine-ineligible population: 69-100%) and overall survival (P range: overall: 89-100%; fludarabine-ineligible: 91-100%) and had the highest probability of being best for all outcomes.
CONCLUSION
Ibrutinib provides superior benefit in survival and safety compared with other front-line treatments of chronic lymphocytic leukemia.
目的
由于比较性证据稀缺，因此进行了一项系统的文献综述和网状荟萃分析，以确定初治慢性淋巴细胞白血病患者干预措施的相对疗效和安全性。
材料与方法
基于通过系统文献综述确定的数据，通过网状荟萃分析估计无进展生存期、总生存期和安全性结果的相对治疗效果。
结果
在所有无进展生存期的两两比较中，依鲁替尼均表现更优（更优概率[P]范围：总体人群：69 - 100%；氟达拉滨不适用人群：69 - 100%）以及总生存期（P范围：总体：89 - 100%；氟达拉滨不适用：91 - 100%），并且在所有结局中表现最佳的概率最高。
结论
与慢性淋巴细胞白血病的其他一线治疗相比，依鲁替尼在生存和安全性方面具有更大优势。
Zotero 插件